Alpharma Inc

Alpharma — Merger or Acquisition (September 2008)

23 slides from Alpharma's merger presentation, Sep 11, 2008

  1. Slide 1: King to Commence Cash Tender Offer for Alpharma at $37 Per Share

    FOR IMMEDIATE RELEASE KING TO COMMENCE CASH TENDER OFFER FOR ALPHARMA AT $37 PER SHARE BRISTOL, TN., September 11, 2008 — King Pharmaceuticals, Inc. (NYSE: KG) today announced that it intends to commence a cash tender offer to acquire all of the outstanding shares of Class A Common Stock of Alpharma

  2. Slide 2: King's Offer to Acquire Alpharma Inc. Creates a Leading Specialty Pharma Company

    (c) King Pharmaceuticals, 2008. No materials contained in this presentation shall be reproduced or redistributed in any form. King's Offer to Acquire Alpharma Inc. Creates a Leading Specialty Pharma Company September 2008

  3. Slide 3: Forward-looking Statements

    Forward-looking Statements This document contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). King Pharmaceuticals, Inc. ("King") disclaims any intent or obligation to update these forward-looking statements, and claims the protection

  4. Slide 4: Presentation Outline

    Presentation Outline 1. Transaction Summary and Rationale 2. King's Strategy 3. King-Alpharma Combination

  5. Slide 5: Transaction Summary and Rationale

    1. Transaction Summary and Rationale

  6. Slide 6: Transaction Update

    Transaction Update King commenced tender offer to acquire Alpharma for $37 per share1 Fully committed financing Filed for HSR approval and confident that regulatory requirements will be met in a timely manner Transaction expected to close by the end of 2008

  7. Slide 7: Enhanced Offer Delivers Superior Value to Alpharma Stockholders

    Enhanced Offer Delivers Superior Value to Alpharma Stockholders Tender offer price of $37 per share in cash provides: 67% premium to Alpharma's closing price on August 4, 2008 (the date of King's initial private written proposal) 54% premium to Alpharma's closing price on August 21, 2008 (the last t

  8. Slide 8: Transaction Creates Stronger Platform for King's Long-Term Growth

    Transaction Creates Stronger Platform for King's Long-Term Growth Creates a leading specialty pharmaceutical company with greater scale and capabilities Expanded portfolio of pain management products - including multiple platform technologies designed to deliver new innovative products Four potentia

  9. Slide 9: King's Strategy

    2. King's Strategy

  10. Slide 10: King Today

    King Today A developer and acquirer of novel branded prescription pharmaceutical products that have significant market potential Focused in three specialty driven markets Neuroscience Hospital Acute Care A leader and partner of choice in bringing innovative, clinically-differentiated medicines and t

  11. Slide 11: King's Current Portfolio

    EpiPen(r) EpiPen(r) Canada Bio-defense products T-62 Oradur(tm) Technology Platform (PTIE)3 Aversion(r) Technology Platform (Acura)4 Thrombi-Gel(r) (surgical indication) Thrombi-Paste(tm) CorVue(r) Remoxy(r) Acurox(tm) Tablets Thrombin-JMI(r) Thrombi-Pad(tm) Thrombi-Gel(r) Epistaxis Kit Skelaxin(r)

  12. Slide 12: Fully-Aligned 690 Person Sales Force

    Sales Force: 415 Avinza(r) Skelaxin(r) Neuroscience/Pain Specialists Sales Force: 155 Avinza(r) Skelaxin(r) Hospital Specialists Sales Force: 120 Thrombin-JMI(r) Thrombi-Gel(r) Thrombi-Pad(tm) Epistaxis Kit Fully-Aligned 690 Person Sales Force Primary Care EXPERIENCED MANAGED CARE TEAM

  13. Slide 13: Neuroscience Portfolio Positions King as a Leader in Pain Management

    DEVELOPMENT MARKETED Remoxy(r) Acurox(tm) Tablets Avinza(r) Neuroscience Portfolio Immediate and Extended Release Abuse-deterrent Platforms Position King as a Leader in Pain Management Skelaxin(r) T-62 Oradur(tm) Technology Platform (PTIE) Aversion(r) Technology Platform (Acura)

  14. Slide 14: Focus on Pain: Patient Landscape

    Focus on Pain: Patient Landscape More than 75 million Americans suffer from pain - more than the number of people with diabetes, heart disease and cancer combined5 An estimated 50 million Americans live with chronic pain, a serious and complex medical condition6 Commonly caused by arthritis, lower b

  15. Slide 15: Issues in the Treatment of Pain - a Complex Societal Issue

    Issues in the Treatment of Pain - a Complex Societal Issue Chronic pain often remains undertreated Despite the availability of effective prescription opioid pain medications Misuse, abuse and diversion of opioid products has significantly influenced physicians' willingness to prescribe them In fact,

  16. Slide 16: Prescription Opioid Abuse - A Significant and Growing Problem

    Prescription Opioid Abuse - A Significant and Growing Problem 5.2 million Americans used prescription pain relievers for non-medical use in 200610 Each day approximately 2,500 teens try abusing prescription painkillers for the first time11 4.3% of high school seniors abused long-acting oxycodone 9.7

  17. Slide 17: Opioid Segments and Market Opportunity

    Immediate Release Opioid Segment $2 Billion15 170 Million TRx's Current Marketplace Vicodin Tylenol w Codeine Percocet Dialaudid Opana IR Various Generics Extended Release Opioid Segment $4 Billion15 19 Million TRx's Current Marketplace OxyContin Duragesic Avinza Kadian MS-Contin Opana ER Various Ge

  18. Slide 18: An Integrated Approach to Growth

    An Integrated Approach to Growth Specialty Driven Markets Corporate Growth Strategy Organic Growth Maximize current product potential Develop pipeline products Enhance capabilities and maximize efficiency Leverage core capabilities and assets Develop partnerships for promising products and technolog

  19. Slide 19: King-Alpharma Combination

    3. King-Alpharma Combination

  20. Slide 20: Combined Company Creates A Diversified Pain Portfolio

    Combined Company Creates A Diversified Pain Portfolio Combined Skelaxin(r) Avinza(r) Remoxy(r) (NDA Filed) Acurox(tm) (Phase III) Kadian(r) Flector(r) Patch Embeda (NDA Filed) Ketoprofen Gel (Phase III) T-62 (Phase II) EpiPen(r) Bio-defense products Vanquix (Phase III) King Skelaxin(r) Avinza(r) Rem

  21. Slide 21: Combined R&D Pipeline

    Combined R&D Pipeline PLATFORM TECHNOLOGIES Phase III Ongoing Topical non-steroidal anti-inflammatory ("NSAID") Ketoprofen in TRANSFERSOME(r) Gel NDA Filed/Priority Review Long-acting morphine tablets Embeda(tm) abuse-deterrent Acurox(tm) and other short-acting abuse-resistant/deterrent opioids Aver

  22. Slide 22: Compelling Transaction

    Compelling Transaction Value creation for both King and Alpharma stockholders Strong strategic fit Opportunity to increase scale and depth in neuroscience/pain Excellent platform for sustainable, long-term growth Proposed combination could receive all necessary regulatory approvals and be completed

  23. Slide 23: End Notes

    End Notes See King's Schedule TO on file with the SEC for the full terms and conditions of the offer Principally from savings in general and administrative expenses, research and development expenses and savings to be achieved by avoiding the expense of hiring additional sales representatives for th

Alpharma — Merger or Acquisition (September 2008) on 6ix